Citations

Showing 10 of 108152 citations.

Biomarkers of Hyperprogression and Pseudoprogression with Immune Checkpoint Inhibitor Therapy
Failing, Jarrett, Dudek, Olivia Anna, Marin‐Acevedo, Julian A. , Chirilă, Răzvan M. , Dong, Haidong , Dronca, Roxana , Failing, Jarrett J, Dronca, Roxana S., Dong, Haidong , Markovic, Svetomir N.

Mayo Clinic

Future Oncology | July 12, 2019 | Volume: 15 | Issue: 22 | Pages: 2645-2656

10.2217/fon-2019-0183 | PMID 31298573 Get It

Assessing Surgical Risk in Idiopathic Portal Hypertension: Some Answers, an Extrapolation, and More Questions
Simonetto, Douglas A. , Kamath, Patrick S. , Shah, Vijay H. , Simonetto, Douglas A

Mayo Clinic

Hepatology | July 12, 2019 | Volume: 70 | Issue: 3 | Pages: 767-770

10.1002/hep.30847 | PMID 31298742 Get It

Ten‐year survivors in AL amyloidosis: characteristics and treatment pattern
Muchtar, Eli , Gertz, Morie A. , Lacy, Martha Q. , Dingli, David , Grogan, Martha , AbouEzzeddine, Omar F. , Hayman, Suzanne R. , Kapoor, Prashant , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Warsame, Rahma , Kourelis, Taxiarchis , Russell, Stephen J. , Lust, John A., Lin, Yi , Zeldenrust, Steven R., Kyle, Robert A. , Kumar, Shaji , Hwa, Yi Lisa, Gonsalves, Wilson , Kourelis, Taxiarchis V, Russell, Stephen, Zeldenrust, Steven, Kumar, Shaji K , Dispenzieri, Angela , Gertz, Morie A , Muchtar, E , Russell, Stephen J , Dingli, David , Lin, Yi , Go, Ronald S. , Buadi, Francis K. , Leung, Nelson , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Dispenzieri, Angela , AbouEzzeddine, Omar F

Mayo Clinic

British Journal of Haematology | July 12, 2019 | Volume: 187 | Issue: 5 | Pages: 588-594

10.1111/bjh.16096 | PMID 31298751 Get It

Summary Improvement in survival in Light chain (AL) amyloidosis has been seen over recent decades, enabling more patients to achieve long‐term survival. Patients with AL amyloidosis who survived ≥10 years from time of diagnosis ( n = 186) were the subject of this study. Ten‐year survivors represented 22% of the total population. These patients were characterized by favourable patient, organ and plasma cell features. Of note, trisomies were less common among 10‐year survivors compared to those who did not survive to 10 years. All‐time best haematological response was complete response in 67%, very good partial response in 30%, partial response in 2% and no response in 1%, with 11% having received a consolidative strategy for inadequate response to first line therapy. The overall organ response rate to first‐line therapy was 76%, which increased to 86% when considering subsequent line(s) of therapy. Forty‐seven percent of the 10‐year survivors did not require a second‐line therapy. The median treatment‐free survival (TFS) among the 10‐year survivors was 10·5 years (interquartile range 7·4‐12·2). On multivariate analysis independent predictors for TFS were the achievement of complete haematological response and lack of cardiac involvement. Long‐term survivors are increasingly seen in AL amyloidosis and present distinct patient, organ and clonal disease features.
Use of the subscapular system by maintaining unilateral decubitus placement without repositioning in microvascular free tissue transplantation
Forte, Antonio J. , Oliver, Jeremie D. , McRae, Matthew , Colasante, Cesar , Eells, Annica C. , Watt, Andrew, Buntic, Rudolph, Buncke, Gregory M. , Safa, Bauback , Forte, Antonio Jorge , Oliver, Jeremie D , Watt, Andrew

Mayo Clinic

Microsurgery | July 12, 2019 | Volume: 40 | Issue: 2 | Pages: 125-129

10.1002/micr.30488 | PMID 31298423 Get It

AbstractBackgroundIn microvascular free‐tissue harvest and transfer, the need for repositioning from lateral decubitus position and the inability to use a two‐team approach are major drawbacks of the subscapular system. We present our experience with the subscapular system for upper and lower extremity reconstruction using a two‐team approach without need for repositioning.MethodsWe conducted a retrospective chart review for all patients undergoing free flap transplant based on the subscapular system to the upper or lower extremity at our microsurgical facility from January 1, 2007 to December 31, 2011. Only cases not requiring intraoperative repositioning were included. Sixty‐four patients underwent the two‐team approach (37 upper extremity and 27 lower extremity transplants). Flap types included latissimus dorsi musculocutaneous, partial superior latissimus, dorsal thoracic fascia, serratus, scapular bone, and thoracodorsal artery perforator, either alone or as chimeric flaps. All patients were placed in the lateral decubitus position for the duration of the surgery.ResultsThe ipsilateral subscapular system was used in 16% of cases for lower extremity defects, where the anterior tibial vessels served as recipient vessels. The contralateral subscapular system was used in all remaining cases for upper extremity or the vast majority for lower extremity (84%) defects, where either the superficial femoral, genicular, popliteal, sural, or posterior tibial vessels served as recipient vessels. With the exception of one partial flap loss secondary to infection, all flaps survived.ConclusionsProper lateral decubitus positioning allows for a two‐team approach without compromising safety or outcomes.
Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device
Wood, David , Krajcer, Zvonimir , Sathananthan, Janarthanan , Strickman, Neil E., Metzger, Chris, Fearon, William F. , Aziz, Mark, Satler, Lowell F. , Waksman, Ron , Eng, Marvin H. , Heimansohn, David, Sampson, Andrew, Coady, Paul , Rodriguez, Roberto , Krishnaswamy, Amar , Lee, Jason T. , Ben‐Dor, Itsik , Moainie, Sina L. , Kodali, Susheel , Yadav, Pradeep , Kozak, Mark, Bacharach, J. Michael, Feldman, Ted , Nanjundappa, Aravinda , Bersin, Robert M., Potluri, Srinivasa , Barker, Colin M. , Bernardo, Nelson L. , Lumsden, Alan B. , Dake, Michael D. , Brown, David L. , Maor, Nathaniel, Nardone, Samuel, Webb, John G. , Investigators, on behalf of the SAFE MANTA Study, Kapadia, Samir , Greenbaum, Adam B. , Szerlip, Molly , Chhatriwalla, Adnan K , O’Neill, Brian Patrick , Guerrero, Mayra , Zhang, Ming , Barleben, Andrew R. , Campbell, John , Cohen, David Jonathan , Lauck, Sandra , O’Neill, William W. , Investigators, on behalf of the SAFE MANTA Study

Mayo Clinic

Circulation: Cardiovascular Interventions | July 12, 2019 | Volume: 12 | Issue: 7 | Pages: No page available

10.1161/circinterventions.119.007258 | PMID 31296082 Get It

Background: Open surgical closure and small-bore suture-based preclosure devices have limitations when used for transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, or percutaneous thoracic endovascular aortic aneurysm repair. The MANTA vascular closure device is a novel collagen-based technology designed to close large bore arteriotomies created by devices with an outer diameter ranging from 12F to 25F. In this study, we determined the safety and effectiveness of the MANTA vascular closure device. Methods and Results: A prospective, single arm, multicenter investigation in patients undergoing transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, or thoracic endovascular aortic aneurysm repair at 20 sites in North America. The primary outcome was time to hemostasis. The primary safety outcomes were accessed site-related vascular injury or bleeding complications. A total of 341 patients, 78 roll-in, and 263 in the primary analysis cohort, were entered in the study between November 2016 and September 2017. For the primary analysis cohort, transcatheter aortic valve replacement was performed in 210 (79.8%), and percutaneous endovascular abdominal aortic aneurysm repair or thoracic endovascular aortic aneurysm repair was performed in 53 (20.2%). The 14F MANTA was used in 42 cases (16%), and the 18F was used in 221 cases(84%). The mean effective sheath outer diameter was 22F (7.3 mm). The mean time to hemostasis was 65±157 seconds with a median time to hemostasis of 24 seconds. Technical success was achieved in 257 (97.7%) patients, and a single device was deployed in 262 (99.6%) of cases. Valve Academic Research Consortium-2 major vascular complications occurred in 11 (4.2%) cases: 4 received a covered stent (1.5%), 3 had access site bleeding (1.1%), 2 underwent surgical repair (0.8%), and 2 underwent balloon inflation (0.8%). Conclusions: In a selected population, this study demonstrated that the MANTA percutaneous vascular closure device can safely and effectively close large bore arteriotomies created by current generation transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, and thoracic endovascular aortic aneurysm repair devices. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02908880.
QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia
Barreto, Jason N. , Cullen, Michael W. , Mara, Kristin C. , Grove, Meagan, Sierzchulski, Amanda G. , Dahl, Nathan J. , Tosh, Pritish K. , Dierkhising, Ross , Patnaik, Mrinal M. , Ackerman, Michael J. , Pawlenty, Amanda G. , Grove, Meagan E, Dierkhising, Ross A, Tosh, Pritish , Mara, Kristin C

Mayo Clinic

Leukemia & Lymphoma | July 12, 2019 | Volume: 60 | Issue: 14 | Pages: 3512-3520

10.1080/10428194.2019.1639165 | PMID 31298598 Get It

Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis
Czaja, Albert J.

Mayo Clinic

Autoimmunity | July 12, 2019 | Volume: 52 | Issue: 4 | Pages: 144-160

10.1080/08916934.2019.1641200 | PMID 31298041 Get It

Towards Clinical Trials in Fuchs Endothelial Corneal Dystrophy: Classification and Outcome Measures—The Bowman Club Lecture 2019
Patel, Sanjay V.

Mayo Clinic

BMJ Open Ophthalmology | July 12, 2019 | Volume: 4 | Issue: 1 | Pages: e000321

10.1136/bmjophth-2019-000321 | PMID 31414054 Get It

The surgical treatment of Fuchs endothelial corneal dystrophy (FECD) has advanced dramatically over the last two decades. Penetrating keratoplasty has been superseded by various iterations of endothelial keratoplasty, and currently, surgical removal of host Descemet membrane without keratoplasty is being investigated. These surgical advances have been accompanied by significant improvement of our understanding of the underlying disease mechanisms, not least the discovery that FECD in western populations is predominantly an intronic trinucleotide repeat expansion disorder in the transcription factor 4 gene that results in RNA toxicity and mis-splicing. Understanding the disease mechanisms augurs well for developing targeted molecular medical therapies, which will require careful clinical investigation through trials to prove their efficacy and safety. As the field advances towards clinical trials, investigators should carefully define the disease state being treated and consider the options for outcome measures relevant to the type of intervention. FECD, and the outcomes of interventions to treat the disease, can be measured in terms of corneal morphology, corneal function and clinical impact. Standardising the approach for defining FECD and careful thought about the outcomes of intervention that are reported will help make the results of future trials for FECD applicable in clinical practice.
Pain and opioid prescriptions vary by procedure after breast surgery
Murphy, Brittany L. , Thiels, Cornelius A. , Hanson, Kristine T. , McLaughlin, Sarah A. , Jakub, James W. , Gray, Richard J. , Ubl, Daniel S. , Habermann, Elizabeth B. , Jakub, James W , Habermann, Elizabeth , Thiels, Cornelius A , Hanson, Kristine

Mayo Clinic

Journal of Surgical Oncology | July 12, 2019 | Volume: 120 | Issue: 4 | Pages: 593-602

10.1002/jso.25636 | PMID 31297826 Get It

AbstractBackgroundWith the opioid epidemic in the United States, evaluating opioid prescribing patterns is essential. We evaluated opioids prescribed at discharge following breast surgery and their association with patient factors and pain scores.MethodsWe retrospectively identified adult patients who underwent a mastectomy for cancer at Mayo Clinic sites from January 2010 to December 2016. Pain scores and prescription data were compared across operations and patient factors by univariate and multivariable analyses.ResultsOf 4021 patients, 3782 (94.1%) received an opioid prescription. Median oral milligram morphine equivalents (MME) were similar across all site‐specific procedure groups (medians ranging from 225 to 375) while pain scores ranged from 1 to 4. Patients undergoing bilateral mastectomy (BM) and immediate breast reconstruction (IBR) reported the greatest pain scores. Pain scores did not vary with age or diagnosis for patients undergoing unilateral mastectomy or BM with lymph node surgery and IBR procedures.On multivariable analysis, variables associated with a MME discharge prescription >Q4 values included age, body mass index, site, year, inpatient status, and pain before discharge >3.ConclusionPatient‐reported pain following breast surgery varied by procedure, while MMEs prescribed remained similar. This suggests current opioid prescribing does not reflect intensity of pain and requires further research to optimize discharge opioid prescribing practices.
Shoulder arthroplasty in patients with upper extremity lymphedema may result in transient or permanent lymphedema worsening
Lee, Julia , Nguyen, Ngoc Tram V. , Shukla, Dave R. , Sperling, John W. , Cofield, Robert H. , Sánchez‐Sotelo, Joaquín , Shukla, Dave, Sanchez-Sotelo, J. , Shukla, Dave R.

Mayo Clinic

Shoulder & Elbow | July 12, 2019 | Volume: 12 | Issue: 1_suppl | Pages: 53-60

10.1177/1758573219859473 | PMID 33343716 Get It

Introduction Upper extremity lymphedema can complicate mastectomy, lymph node dissection, and radiation. The purpose of this study is to present the outcomes of shoulder arthroplasty in patients with lymphedema. Methods The 19 shoulders with a shoulder arthroplasty and lymphedema on the surgical side (6 anatomic, 12 reverse, 1 hemiarthroplasty) were followed for four years (1–10 years). There were 2 males and 17 females; average age was 67.8 (48–86) years. Breast carcinoma was the most common reason for lymphedema (75%). A dedicated lymphedema questionnaire could be completed for 14 shoulders. Results Pain improved from moderate or severe preoperatively to no or mild in 18 shoulders. Motion improved in elevation (55° preoperatively, 107° at last follow-up), external rotation (14°, 43°), and internal rotation (sacrum, L5). Complications included an acromion stress fracture with a deep infection (1), deep infection (1), superficial infection (1), and glenoid loosening (1). Lymphedema worsened in nine cases, but worsening was permanent in only four. Currently, lymphedema treatment is being performed by 93% of survey respondents. No patients reported lymphangitis or lymphangiosarcoma. Conclusion Shoulder arthroplasty for an upper extremity with lymphedema provides substantial improvements in pain and motion; however, infection is a concerning complication. Fifty percent of the patients will experience worsening of their lymphedema and in 20% worsening may be permanent.